Drug Profile
Ispronicline
Alternative Names: AZD-3480; RJR-1734; TC 01734; TC-1734; TC-1734-112Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator R. J. Reynolds Tobacco Company; Targacept
- Developer AstraZeneca; Targacept
- Class Amines; Neuroprotectants; Nootropics; Pyridines; Small molecules
- Mechanism of Action Alpha4 beta2 nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders
Most Recent Events
- 14 Jul 2014 Discontinued - Phase-II for Alzheimer's disease in USA, Czech Republic, Romania, Slovakia and Ukraine (PO)
- 29 Apr 2013 Targacept completes enrolment in its phase IIb trial for Alzheimer’s disease in USA, Czech Republic, Romania, Slovakia & Ukraine
- 05 Mar 2013 Ispronicline is no longer licensed to AstraZeneca worldwide